ERAS News and Press, Erasca Inc. From 05/03/22

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank ...

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Jean Liu ...

ERAS-007 is a potent and selective small molecule ERK1/2 inhibitor with long target residence time, which promotes sustained RAS/MAPK pathway inhibition ERAS-601 is a potent and selective small molecule SHP2 inhibitor with broad anti-tumor activity that blocks oncogenic signal t...

Virtual event on Tuesday, April 12 at 4:30 PM ET will feature key opinion leader (KOL) Scott Kopetz, M.D., Ph.D., from MD Anderson Cancer Center Company and KOL to discuss an overview of unmet medical needs and therapeutic opportunities in cancers driven by the RAS/MAPK pathway,...

Five ongoing clinical trials evaluating candidates ERAS-007 (ERKi), ERAS-601 (SHP2i), and ERAS-801 (CNS-penetrant EGFRi) Initial Phase 1b data for HERKULES-1 and Phase 1 data for FLAGSHP-1 expected in H2 2022 Robust balance sheet with cash of $459 million SAN...

Erasca (NASDAQ:ERAS) entered a clinical trial collaboration and supply agreement with Eli Lilly (NYSE:LLY) for cetuximab (ERBITUX). Erasca said the agreement will support an ongoing phase 1b/2 HERKULES-3 trial evaluating ERAS-007 in various combinations, including with the encorafenib (B...

ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated clinically in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant mCRC Erasca previously signed a clinical trial collaboration and supply agreement with Pfizer for encorafenib for ...

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present six...

The following slide deck was published by Erasca, Inc. in conjunction with this event. For further details see: Erasca (ERAS) Investor Presentation - Slideshow

SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Gugg...